An interventional study of XVIVO Heart Assist Transport System in Heart Failure, sponsored by XVIVO Perfusion. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 197 studies in Heart Failure with a site in Belgium — 27 open to participants now, 45 under way, 8 of them phase 3. Heart Failure · Belgium.
Among the 197 studies in Heart Failure with a site in Belgium, this one is the 142nd largest by planned enrollment of the 155 interventional ones that give a count, is one of 12 that started in 2024, is one of 78 with no phase, reaches primary completion later than 21 of the 44 other live ones, and was the 196th registered.
6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.
Browse Heart Failure studies →27 of the 197 studies in Heart Failure with a site in Belgium are open now. Recruiting first, the newest first:
Oslo University Hospital · Sites in Belgium, United States, France and 7 more countries
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages up to 18
Fondazione Don Carlo Gnocchi ETS · Sites in Belgium, Italy, Portugal and 1 more country
Ages 18+
Ziekenhuis Oost-Limburg · Sites in Belgium
Ages 18+
Bayer · Sites in Belgium, United States, Argentina and 20 more countries
Ages 6 mo–17 yrs
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
197 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 27 · Phase 3 44 · Phase 4 9
First in 1983; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 76 across 4,053 interventional studies indexed under Heart Failure.
Median enrollment 262 across the 155 interventional studies, 450 across the 42 observational. Of the 137 that completed or were terminated, 59 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
141 of 197 have an industry lead sponsor. The 10 most frequent:
XVIVO Perfusion is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
XVIVO Perfusion has 4 studies filed under Heart Failure — fewer than ten, so there is no comparison to draw.
6 of the studies in Heart Failure with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06661876Universitaire Ziekenhuizen KU LeuvenCardiac RadiothErapy For hEart faiLure | 2026-12-31 |
| NCT07823998Jean-Benoît Le Polain de WarouxCoffee Use, Physical Activity and Symptomatic Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction and an ICD | 2027-04 |
| NCT07556588XVIVO PerfusionXVIVO Heart Transplant Study in Clinical Practice | 2027-05-15 |
| NCT07252856Fondazione Don Carlo Gnocchi ETSTranscultural Digital Solutions in Phase III Cardiac Rehabilitation | 2027-06-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 197 studies in Heart Failure with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HOPE for All is a clinical investigation to support the use of hypothermic oxygenated perfusion (HOPE) using a revised XVIVO Heart Assist Transport System in a real- world setting.
The trial will investigate the application of HOPE in a broad population of Donation after Brain Death (DBD) and Donation after Circulatory Death (DCD) donor hearts transplanted to any listed adult patient.
The hypothesis is that the use of HOPE is safe and feasible for any adult patient awaiting a heart transplantation.
Primary objective is to evaluate patient survival in the real world setting after heart transplantation, where HOPE using the revised XVIVO Heart Assist Transport System is used for donor heart preservation.
Secondary objective(s) are to evaluate patient outcomes and graft function post-transplant.
HOPE for All is a prospective, single-armed single-centre proof-of-consept trial.
HOPE for All will include a total of 20 subjects transplanted with donor hearts using the revised XVIVO Heart Assist Transport System and will evaluate transplant outcomes such as patient survival, post-transplant complications and graft function for a period of 12 months post-transplant.
The investigation will be conducted at 1 heart transplant center in Belgium who has thorough experience using the XVIVO Heart Assist Transport System for both DBD and DCD transplants.
The study will not include a control group as this is a proof-of-concept study
Inclusion Criteria Recipient:
Inclusion Criteria Heart Donor:
Exclusion Criteria Recipient:
Exclusion Criteria Heart Donor:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: XVIVO Heart Assist Transport System
Revised XHAT
Also known as: Hypothermic oxygenated perfusion - HOPE, Direct procurment, Non-Ischemic Heart Preservation NIHP
Patient Survival
Time frame: 30 days post-transplant
Cardiac related mortality at 30 days post-transplant
Time frame: 30 days post-transplant
Incidence of Mechanical circulatory support within 30 days post-transplant
Time frame: 30-days post-transplant
Incidence of severe Primary Graft Dysfunction (PGD) at 24 hours post-transplant
Time frame: 24 hours post-transplant
Incidence of Primary Graft Dysfunction (PGD) RV at 24 hours post-transplant
Time frame: 24 hours post-transplant
Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 24 hours and 30 days post-transplant
Time frame: 24 hours and 30 days post-transplant
Duration of initial ICU stay after the index procedure
Time frame: 30-days post-transplant
Incidence of biopsy proven rejections > 1 ACR (leading to changed immunosuppressive regime) within 30 days post-transplant
Time frame: 30 days post-transplant
Incidence of hearts perfused on the investigational device which is not used for transplantation
Time frame: From enrollment to the end of recruitment
Cardiac related mortality at 6 and 12 months post-transplant
Time frame: 6 and 12 months post-transplant
Cardiac function as assessed by left ventricular ejection fraction (LVEF) at 6 and 12 months post-transplant
Time frame: 6 and 12 months post-transplant
Number of days until hospital discharge from index procedure 6 and 12 months post-transplant
Time frame: 6 and 12 months post-transplant
Incidence of biopsy proven rejections > 1 ACR leading to changed immunosuppressive regime within 12 months post-transplant
Time frame: Within 12 months post-transplant
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.
Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 33 months is close to that.
Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
XVIVO Perfusion